



Stockholm, 2019-03-12

PRESS RELEASE

A patent application with significant potential has been submitted in the US.

QuiaPEG Pharmaceuticals Holding AB (publ.) announces that a patent application within the fast-growing area of antibody drug conjugates* (ADC) has been submitted to the American patent office (USPTO). Granting of the application will mean that QuiaPEG will have patent protection up to and including 2013.

A year ago, QuiaPEG submitted a so-called provisional patent application for ADC in the USA. The company has since then worked on further developing the existing releasable technology platform, Uni-Qleaver®, for use with ADCs. The extensive chemical and pre-clinical development work has yielded valuable results, which now form the basis of the above-mentioned patent application.

ADC is a fast-growing area in the development of new and more targeted cancer drugs and is expected to generate approximately \$ 10 billion in 2025. There are currently a handful of approved drugs in this area and just under 200 ADCs undergoing clinical trials.

"The need within oncology for a chemistry platform that gives a more selective and controlled release of cytotoxins inside a specific tumor is judged to be very great, and this should provide QuiaPEG with many new and potentially significant business opportunities in the future," says Marcus Bosson, CEO.

* Antibody Drug Conjugates, ADC, consists of three components: a cytotoxin, a monoclonal antibody, and a biodegradable linker, linking the two moieties. The ADC method combines recognition of tumor-specific antigens with selective release of cytotoxic substances into cancer cells.

For further information please contact:

Marcus Bosson
Chief Executive Officer
Tel: +46 (0) 70 693 12 53

E-mail: marcus.bosson@quiapeg.com

www.quiapeg.com